Effects of b2 agonists on post-thoracotomy XXXX incidence.

@entity1 @entity19 @entity1109 @entity158 @entity25255 @entity1118 @entity9
BACKGROUND: Pre-clinical research has shown b2 -adrenoceptors to be essential for the antiallodynic action of antidepressant drugs in @entity19 models of @entity9 and that sustained treatment with b2 -agonists has an antiallodynic action. Here, we clinically investigated whether chronic b2 -agonist treatments may influence the incidence of post-thoracotomy @entity1118 , @entity158 that recurs or persists along a thoracotomy scar more than 2  months after surgery, either @entity1109 . METHODS: We conducted an epidemiological study on @entity1 operated by thoracotomy. Demographic data, medical history and treatments concomitant to the surgery were recorded at a follow-up visit. Information on perioperative treatments was collected from the anaesthesia records and confirmed by the @entity1 . In @entity1 with @entity158 at the surgery level, post-thoracotomy @entity1118 was assessed by clinical examination and numeric scale. Physical examination and @entity25255 questionnaire were used to discriminate @entity9 at scar level. RESULTS: One hundred and eighty-nine @entity1 were included. Eighty-one @entity1 reported persisting @entity158 , with neuropathic characteristics in 58 of them (30% of the 189 @entity1 ). The most common chronic drugs during the perioperative period were inhaled b2 -agonists (28.6%). The chronic use of b2 -agonists was an independent predictor of thoracic @entity9 (but not of @entity9 ) and was associated with a five-fold decrease in the relative incidence of @entity9 [OR  =  0.19 (0.06-0.45)]. CONCLUSIONS: These data suggest a possible influence of chronic b2 -agonist treatments on @entity9 secondary to thoracotomy. This apparent preventive effect of b2 -agonist treatments should warrant controlled clinical trials.
